IP Library › Granted Patent US 12,383,531
Granted Patent B2
US 12,383,531 · App. 16/097,160 · Granted Aug 12, 2025

PLA2 inhibitors for treatment of pathological conditions caused by hymenoptera envenomation, such as hemolysis, cerebral edema, and acute kidney injury

Inventor: Matthew R. Lewin (Corte Madera, CA)
Assignee: Ophirex, Inc.
A61K31/4045A61K31/192A61K45/06A61P39/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,383,531
App. No.
16/097,160
Granted
Aug 12, 2025
Kind
B2
Abstract

Provided are methods for treatment of pathological conditions causing hemolysis, cerebral edema, acute kidney injury and non-anaphylactic shock, including envenomation, trauma, cerebral malaria and mast-cell diseases using at least one PLA2 inhibitor, alone or in combination with other agents. The unexpected versatility of PLA2 inhibitors, their dosage forms and combinations make them candidates as essential medicines for the developing world.

Claims (17)

1. A method for treating a subject who has previously been envenomed by hymenoptera; comprising administering to the subject an effective amount of a small molecule inhibitor of secretory phospholipase A2 (sPLA2),

wherein the sPLA2 inhibitor is selected from varespladib, methylvarespladib, and pharmaceutically acceptable salts thereof.

2. A method for treating a subject who has previously been envenomed by hymenoptera; comprising administering to the subject an effective amount of a small molecule inhibitor of secretory phospholipase A2 (sPLA2),

wherein the sPLA2 inhibitor is selected from compounds having the structure shown in Formula I, and pharmaceutically acceptable salts thereof:

wherein R is H (Compound 4) or CH 3 (AZD2716).

3. The method of claim 1 , which is a method of treating a subject who has been envenomed by swarming hymenoptera.

4. The method of claim 1 , wherein the hymenoptera are bees or wasps.

5. The method of claim 1 , wherein the amount of the sPLA2 inhibitor is effective in preventing or delaying impaired kidney function in the subject caused by the venom.

6. The method of claim 1 , wherein the amount of the sPLA2 inhibitor is effective in preventing or delaying hemolysis or cerebral edema in the subject caused by the venom.

7. The method of claim 1 or claim 2 , which further comprises administering to the subject a statin simultaneously or sequentially with the administering of the sPLA2 inhibitor.

8. The method of claim 7 , wherein the statin is selected from atorvastatin, cerivastatin, fluvastatin, lovastatin, a monacolin, mevastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, and pharmaceutically acceptable salts thereof.

9. The method of claim 1 or claim 2 , wherein the subject is also administered with an antibody specific for hymenoptera venom.

10. The method of claim 1 , wherein the small molecule inhibitor of sPLA2 is administered to the subject within 12 hours following the envenoming.

11. The method of claim 1 or claim 2 , wherein the small molecule inhibitor of sPLA2 is administered to the subject as field treatment upon realization that the subject has been envenomed by the hymenoptera.

12. The method of claim 1 , wherein the small molecule inhibitor of sPLA2 is administered to the subject orally or by injection.

13. The method of claim 1 or claim 2 , which further comprises administering to the subject a metalloproteinase inhibitor simultaneously or sequentially with the administering of the sPLA2 inhibitor.

14. The method of claim 13 , wherein the metalloproteinase inhibitor is prinomastat or vorinostat.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 27, 2018
From: LEWIN, MATTHEW R.
To: OPHIREX, INC.
Reel/Frame 047593/0290 →
Continuity (4)
Provisional Application 62423693 · Nov 17, 2016
Provisional Application 62340075 · May 23, 2016
Provisional Application 62329611 · Apr 29, 2016
Related Publication 20210220332A1 · Jul 22, 2021
References Cited (57)
US 5064817A · Yedgar et al. · 1991 [cited by applicant]
US 6433001B1 · Bach · 2002 [cited by examiner]
US 10786483B2 · Klein · 2020 [cited by examiner]
US 11000506B2 · Lewin · 2021 [cited by applicant]
US 20080096963A1 · Theirry et al. · 2008 [cited by applicant]
US 20080249027A1 · Cunningham · 2008 [cited by examiner]
US 20090234011A1 · Goldstein · 2009 [cited by applicant]
US 20100204249A1 · Hislop et al. · 2010 [cited by applicant]
US 20110269786A1 · Hislop et al. · 2011 [cited by applicant]
US 20140087003A1 · Cisneros · 2014 [cited by applicant]
US 20150224094A1 · Lewin · 2015 [cited by applicant]
AU 2001278602A1 · 2002 [cited by applicant]
EP 3448378B1 · 2024 [cited by applicant]
WO 1999029726A1 · 1999 [cited by applicant]
WO 2005023310A2 · 2005 [cited by applicant]
Touaibia et al., Inhibition of Secreted Phospholipase A2. 4-Glycerol Derivatives of 4,5-Dihydro-3-(45-tetradecyloxybenzyl) 1,2,4-4H-oxadiazol-5-one with Broad Activities. Journal of Medicinal Chemistry, 2007, 50, 1618-1… [cited by examiner]
Ichihara et al., “Cajucarinolide and Isocajucarinolide: Anti-Inflammatory Diterpenes from Croton caj ucara”, Planta Medica, vol. 58, No. 06, Jan. 5, 2007, pp. 549-551. [cited by applicant]
Magrioti et al., “Phospholipase A [cited by applicant]
EP Application 17790643.5, ESSR, Mar. 10, 2020, 10 pages. [cited by applicant]
El-Kik et al., “Neutralization of Apis mellifera bee venom activities by suramin”, Toxicon, Mar. 58, 2013, pp. 55-62 (67). [cited by applicant]
Folmer et al., “Marine natural products targeting phospholipases A [cited by applicant]
Lewin et al., “Varespladib (LY315920) Appears to Be a Potent, Broad-Spectrum, Inhibitor of Snake Venom Phospholipase A2 and a Possible Pre-Referral Treatment for Envenomation”, Toxins, 2016, pp. 1-16, 8(9). [cited by applicant]
Teixeira-Cruz et al., “A Novel Apilic Antivenom to TreatMassive, Africanized Honeybee Attacks: A Preclinical Study from the Lethality to Some Biochemical and Pharmacological Activities Neutralization”, Toxins, Jan. 5, 2… [cited by applicant]
“Chemical Components Of Insect Venoms”, Compound Interest 2014, obtained from www.compoundchem.com, accessed Jun. 22, 2021, 1 page. [cited by applicant]
Wouters et al., “Estimated Research and Development Investment Needed to Bring a NewMedicine to Market, 8 2009-2018”, JAMA, Mar. 3, 2020, pp. 844-853, vol. 323, No. 9. [cited by applicant]
Chauffe, R. et al. “Recent Developments with Lipoprotein-Associated Phospholipase A [cited by applicant]
Dongol, Y. et al. “Hymenoptera Stings and the Acute Kidney Injury.” [cited by applicant]
International Search Report and Written Opinion received in International Patent Application No. PCT/US2017/030436, dated Sep. 21, 2017. 13 pages. [cited by applicant]
Klein et al., “U.S. Appl. No. 62/303,647”, filed Mar. 4, 2016, 20 pages. [cited by applicant]
Klein et al., “U.S. Appl. No. 62/308,673”, filed Mar. 15, 2016, 22 pages. [cited by applicant]
Lewin., “U.S. Appl. No. 63/329,611”, filed Apr. 29, 2016, 22 pages. [cited by applicant]
Lewin, “U.S. Appl. No. 62/423,693”, filed May 10, 2017, 62 pages. [cited by applicant]
Lewin, “U.S. Appl. No. 63/340,075”, filed May 23, 2016, 29 pages. [cited by applicant]
Balsinde et al., “Regulation and Inhibition of Phospholipase A2”, Annual Review of Pharmacology and Toxicology, vol. 39, Apr. 1999, pp. 175-189. [cited by applicant]
Boilard et al., “Secreted Phospholipase A2 Inhibitors are Also Potent Blockers of Binding to the M-Type Receptor”, Biochemistry, vol. 45, Oct. 2006, pp. 13203-13218. [cited by applicant]
Carvalho et al., “Snake Venom PLA2s Inhibitors Isolated from Brazilian Plants: Synthetic and Natural Molecules”, BioMed Research International, vol. 2013, Jan. 2013, pp. 1-8. [cited by applicant]
Clark et al., “Potential Therapeutic Uses of Phospholipase A2 Inhibitors”, Expert Opinion on Therapeutic Patents, vol. 14, 2004, pp. 937-950. [cited by applicant]
Filho et al., “Enzymatic and Structural Characterization of New PLA2 Isoform Isolated from White Venom of Crotalus Durissus Ruruima”, Toxicon, vol. 53, Jan. 2009, pp. 104-114. [cited by applicant]
Howes et al., “Neutralization of the Haemorrhagic Activities of Viperine Snake Venoms and Venom Metalloproteinases Using Synthetic Peptide Inhibitors and Chelators”, Toxicon, vol. 49, Apr. 2007, pp. 734-739. [cited by applicant]
Laustsen et al., “From Fangs to Pharmacology: The Future of Snakebite Envenoming Therapy”, Current Pharmaceutical Design, vol. 22, Jun. 2016, pp. 1-24. [cited by applicant]
Lewin et al., “Varespladib (LY315920) Appears to be a Potent, Broad-Spectrum, Inhibitor of Snake Venom Phospholipase A2 and a Possible Pre-Referral Treatment for Envenomation”, Toxins, vol. 8, No. 9, Aug. 2016, pp. 1-16. [cited by applicant]
Marchi-Salvador et al., “Crystal Structure of a Phospholipase A(2) Homolog Complexed with P-Bromophenacyl Bromide Reveals Important Structural Changes Associated with the Inhibition of Myotoxic Activity”, Biochimica et … [cited by applicant]
Marcussia et al., “Snake Venom Phospholipase A2 Inhibitors: Medicinal Chemistry and Therapeutic Potential”, Current Topics in Medicinal Chemistry, vol. 7,, Feb. 2007, pp. 743-756. [cited by applicant]
Application No. MX/A/2018/013084 , Notice of Allowance, Mailed On Jan. 19, 2022, 2 p. Machine translation begins on p. 3 (by google translate on Feb. 18, 2022). [cited by applicant]
Oslund et al., “Highly Specific and Broadly Potent Inhibitors of Mammalian Secreted Phospholipases A2”, Journal of Medicinal Chemistry, vol. 51, Aug. 2008, pp. 4708-4714. [cited by applicant]
Pereafiez et al., “The Biflavonoid Morelloflavone Inhibits the Enzymatic and Biological Activities of a Snake Venom Phospholipase A2”, Chemico-Biological Interactions, vol. 220,, Sep. 2014, pp. 94-101. [cited by applicant]
Rucavado et al., “Effect of the Metalloproteinase Inhibitor Batimastat in the Systemic Toxicity Induced by Bothrops Asper Snake Venom: Understanding the Role of Metalloproteinases in Envenomation”, Taxicon, vol. 43, Apr… [cited by applicant]
Samy et al., “Therapeutic Application of Natural Inhibitors Against Snake Venom Phospholipase A2”, Bioinformation, vol. 8, No. 1, Jan. 2012, pp. 48-57. [cited by applicant]
Sunitha et al., “Neutralization of Haemorrhagic Activity of Viper Venoms by 1-(3-Dimethylaminopropyl)-1-(4-Fluorophenyl)-3-oxo-1,3-Dihydroisobenzofuran-5-Carbonitrile”, Basic & Clinical Pharmacology & Toxicology, vol. 1… [cited by applicant]
Ticli et al., “Rosmarinic Acid, a New Snake Venom Phospholipase A2 Inhibitor from Cordia Verbenacea (Boraginaceae): Antiserum Action Potentiation and Molecular Interaction”, Toxicon, vol. 46, Sep. 2005, pp. 318-327. [cited by applicant]
Wang et al., “Exploration of the Inhibitory Potential of Varespladib for Snakebite Envenomation”, Molecules, vol. 23, No. 2, Feb. 2018, pp. 1-13. [cited by applicant]
Rodrigues da Silva et al., Sulfated Galactan from Palisada Flagellifera Inhibits Toxic Effects of Lachesis Muta Snake Venom, Marine Drug, vol. 13, No. 9, 2015, pp. 3761-3775. [cited by applicant]
Song et al., “Subcellular Membrane Impairment and Application of Phospholipase A2 Inhibitors in Endotoxic Shock”, Injury, vol. 30, No. 1, Jan. 1999, pp. 9-14. [cited by applicant]
Appeal 2022-001944, Order by Patent Trial and Appeal Board (PTAB) mailed on May 21, 2024, 42 pages. [cited by applicant]
Giordanetto et al., Discovery of AZD2716: A Novel Secreted Phospholipase A2 (sPLA2) Inhibitor for the Treatment of Coronary Artery Disease, ACS Medicinal Chemistry Letters, vol. 7, No. 10, Aug. 9, 2016, pp. 884-889. [cited by applicant]
Nicholls et al., Varespladib and Cardiovascular Events in Patients with an Acute Coronary Syndrome: the VISTA-16 Randomized Clinical Trial, The Journal of the American Medical Association, vol. 311, No. 3, Jan. 15, 2014… [cited by applicant]
Wang et al., Phospholipase A2 Inhibitor Varespladib Prevents Wasp Sting-induced Nephrotoxicity in Rats, Toxicon: Official Journal of the International Society on Toxicology, vol. 215, Jun. 11, 2022, pp. 69-76. [cited by applicant]
Cited By (1)
US 12,714,693